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Abstract
Background: Few risk factors have been identified for the development of calcinosis among patients with Juvenile
Dermatomyositis, and currently no clinical phenotype has been associated with its development. We analyzed a
large database of patients to further elucidate any relationships among patients with and without calcinosis.
Method: The CARRA legacy registry recruited pediatric rheumatology patients from 55 centers across North
America from 2010 through 2014, including over 650 subjects with Juvenile Dermatomyositis. We compared
the demographic characteristics, clinical disease features and treatment histories of those with and without
calcinosis using univariate and multivariate logistic regression.
Results: Of the 631 patients included in the analysis, 84 (13%) had a current or prior history of calcinosis. These
patients were statistically more likely to have longer durations of disease prior to diagnosis and treatment, have
lipodystrophy and joint contractures, and to have received intravenous immune globulin or rituximab as treatments.
Conclusions: Calcinosis is found more often in patients with prolonged active disease, severe disease, and certain
clinical features such as lipodystrophy and joint contractures. When these factors are combined with other
known associations and predictors, groups of at-risk patients can be more effectively identified, treated and
studied to improve overall outcomes.
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Introduction
As the most common inflammatory myopathy of child-
hood, Juvenile Dermatomyositis (JDM) affects 3.2 per
million children annually in the United States [1]. Before
the widespread use of glucocorticoids, followed by disease-
modifying anti-rheumatic drugs (DMARDs), JDM was fatal
in one-third of cases [2–4]. More recent studies have
shown mortality as low as 3.1% [5] while simultaneously
highlighting persistent morbidity from active disease or its
sequelae [6–8]. An enigmatic source of morbidity comes
from calcinosis, the dystrophic deposition of the mineral
calcium hydroxyapatite in the skin, soft tissues or muscle,
which is reported to occur in approximately 40% of patients
[9]. When surveyed in 2016 regarding their experience and
approach to assessing and treating JDM calcinosis, less than
20% of pediatric rheumatologists have treated more than
10 cases. In addition, the majority who have such experi-
ence have practiced for more than 20 years. [10].
There have been many studies attempting to identify
risk factors or associations of calcinosis in JDM patients
in order to further define the at-risk patient population.
Actionable risk factors previously identified include a
delay to treatment and/or prolonged disease duration
[5, 11, 12] and initial treatment intensity [13, 14]; prog-
nostic factors included race [15–17], male sex [15], under-
lying cardiac disease [18, 19], presence of joint contractures
[18], and presence of certain myositis-specific antibodies
[20, 21]; genetic risks were also identified [22, 23]. However,
in some large cohorts, no risk factors are identified [24].
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Due to the rarity of JDM as a whole, and with calcinosis oc-
curring in less than half of patients, there have been few
studies of large numbers of patients with calcinosis. Lacking
among all of these studies is a clinical phenotype of patient
disease features that might also be associated with the de-
velopment of calcinosis, apart from prolonged or severe
disease, which has many connotations depending on the
publication. Further, regarding treatment, much attention
has been paid to the amount and duration of glucocorticoid
use [25–27], but there has been no assessment made of
whether the use of biologic treatments, now widely used,
are associated with calcinosis. Our aim was to address these
questions by analyzing a large patient registry of JDM pa-
tients with assessments of clinical features and treatment
histories, including those who developed calcinosis during
the course of follow-up.
Methods
The Childhood Arthritis and Rheumatology Research
Alliance (CARRA) developed a multicenter registry for
pediatric rheumatologic diseases across North America.
Patients were enrolled from May 30, 2010 through Octo-
ber 31, 2014 from 55 CARRA centers. JDM was among
the diseases included in the registry, and any patients
whose disease began before 18 years of age and were less
than 21 years of age at the time of enrollment were eli-
gible for inclusion. All JDM patients must have met the
Bohan and Peter criteria for diagnosis, modified to allow
magnetic resonance imaging as an acceptable diagnostic
modality [28].
Data collection
All data were submitted by the enrolling physician at
each site after collecting clinical data using report forms
for general information, demographics, functional and
quality-of-life measures and JDM-specific information at
baseline and follow-up visits. At baseline (the time of
registry enrollment), the presence of several disease
manifestations was assessed (present, absent or not
assessed), including proximal muscle weakness (desig-
nated mild, moderate or severe), characteristic disease
rashes, lipodystrophy, skin ulceration, periungal telangi-
ectasias and contractures (not specified as due to muscle
or joint disease). There was also documentation of pres-
ence or absence of other disease features (current, past
or never), including calcinosis, small or large joint arth-
ritis, dysphagia or dysphonia and organ involvement
(cardiac, gastrointestinal or lung). At follow-up visits,
these same clinical features were documented if present
or absent. At enrollment, the patient’s history of biologic
medication use was assessed by current or prior use, and
at follow-up visits, it was assessed if any biologic medi-
cation had been used in the visit interval. Patient data
were kept in a centralized database by CARRA and after
study approval were transmitted as a coded, deidentified
dataset under code access agreement to the study team.
This study was exempt from the Washington University
School of Medicine institutional review board by not
constituting human subject research.
Statistical analyses
All analyses were performed using SAS version 9.4 (SAS
Institute Inc) and R version 3.3.1 (R Project for Statis-
tical Computing). Any patients lacking requisite data in
calcinosis were excluded. A cross-sectional analysis of
baseline data in all JDM patients was performed com-
paring those with any history (current or past) of calci-
nosis to those without (never) in respect to demographic
characteristics, clinical and disease features, and treat-
ment with biologic agents and glucocorticoids. To calcu-
late the duration of symptoms prior to treatment, the
difference between symptom onset date and first
rheumatology visit date was used, measured in months.
Due to small respective numbers of each form of organ
involvement (i.e. cardiac arrhythmia), a composite meas-
ure combining all different forms of organ toxicity (i.e.
cardiac, pulmonary and gastrointestinal) was also used.
For similar reasons, different tumor necrosis factor
(TNF)-alpha inhibitors and interleukin-1 inhibitors were
grouped as single entities for the purpose of analysis. In-
formation on glucocorticoid treatment was collected in
the registry by documenting only current or prior re-
ceipt of intravenous pulse steroids and/or systemic daily
long-term use of specified durations. No dosages or in-
tervals were recorded. In order to study possible effect
of high or low glucocorticoid exposure, selected patients
were grouped for the purpose of analysis. A patient with
high steroid exposure was defined as one with a current
or prior history of intravenous pulse steroids and
current or prior use of daily systemic corticosteroids of
at least one-month duration. Differences between pa-
tients with and without calcinosis were analyzed with
t-test or Mann-Whitney-U tests for continuous variables
as appropriate, while comparisons for categorical vari-
ables used Chi-square or Fisher’s exact tests as appropri-
ate. Statistically significant measures at the alpha level of
0.05 on univariate analyses were included in multivariate
logistic regression modeling. Stepwise selection method
during multivariate logistic regression modeling was
used to adjust for collinearity of certain clinical features,
where a variable had to be significant at the 0.25 level to
be entered into the model and significant at 0.15 to stay.
At the following step, the final model included variables
significant at 0.05. A Forest Plot using R program was
performed to illustrate the odds ratio and associated
95% confidence interval that were significant in the lo-
gistic regression model.
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Results
A total of 654 patients with JDM were enrolled in the
CARRA legacy registry. Twenty-three patients were ex-
cluded who lacked information on calcinosis, including
five patients with follow-up data but no information at
baseline. The remaining 631 were included in analysis,
with 84 patients (13.3%) having a current or prior his-
tory of calcinosis at the time of enrollment. The registry
cohort included 454 females (72%) and 177 males (28%)
with a median age at diagnosis of 5.6 years. Caucasian
race comprised 82% of patients, while Hispanic ethnicity
represented 15% of patients, and African-American,
13%. The majority of patients were categorized as ‘prob-
able’ JDM, which was used to define 490 patients (78%),
while 48 (7.6%) were categorized as definite. Only nine
patients (1.4%) were designated as amyopathic, and the
remaining 13% had no selected category. Across the en-
tire cohort, 38% had current or prior treatment with a
biologic medication (Table 1).
Clinical disease features
When comparing those with a history of calcinosis to
those without, there were statistically significant differ-
ences in the proportions of the two groups for several
demographic and clinical features (Table 2). There was
no difference between groups in regards to cardiac, lung
or gastrointestinal involvement, but when these events
were combined as a single composite feature, “any organ
involvement”, the differences were statistically signifi-
cant. In univariate analysis, statistical significance was
maintained for characteristics of male sex (OR 1.811,
95% CI 1.123–2.919), time to diagnosis (OR 1.029, 95%
CI 1.016–1.043) and African-American race (OR 2.264,
95% CI 1.270–4.038). For other clinical disease features,
lipodystrophy (OR 5.993, 95% CI 2.588–13.874), joint
contractures (OR 5.343, 95% CI 2.964–9.635), cutaneous
ulcerations (OR 3.748, 95% CI 1.787–7.862), Gottron’s
or heliotrope rashes (OR 1.754, 95% CI 1.099–2.800), V
or shawl sign (OR 2.410, 95% CI 1.083–5.361) and organ
involvement (OR 2.506, 95% CI 1.127–5.573) also main-
tained significance (Table 2) and were included in multi-
variate analysis.
Treatment with biologics
In the overall cohort, 242 (38.4%) patients experienced
current or prior use with a biologic agent. Intravenous
immune globulin (IVIG) was the most common with
225 (35.6%) patients exposed followed by anti-TNF-
alpha therapy with 35 (5.5%) patients. Etanercept com-
prised the majority of anti-TNF-alpha therapy with 22
patients reporting use, representing 63% of all anti-
TNF-alpha therapy. Rituximab was used in 26 (4.1%) pa-
tients. When comparing patients with a history of calci-
nosis to those without, statistical significance between
groups was maintained on univariate analysis for all
treatments, except anti-IL1 agents as follows: Rituximab
(OR 6.345, 95% CI 2.825–14.245), IVIG (OR 2.353 95%
CI 1.479–3.743), anti-TNF-alpha (OR 3.797, 95% CI
1.812–7.960) and abatacept (OR 13.317, 95% CI 1.194–
148.514). All were included in multivariable analysis ex-
cept abatacept, since it was only used in three patients
overall, and despite positive odds ratio had an extremely
wide confidence interval (Table 3).
In the multivariable analysis including clinical features and
treatments, the only predictors of association with calcinosis
were increased time to diagnosis (OR 1.029, 95% CI 1.013–
1.045), lipodystrophy (OR 3.038, 95% CI 1.014–9.106), joint
Table 1 Cohort characteristics, n = 631
Characteristics
















History of Calcinosis 84 13.3











High glucocorticoid exposurec (n = 572) 316 50
aComposite which includes etanercept, infliximab, adalimumab, certolizumab,
golimumab
bComposite which includes anakinra, canakinumab, rilonacept
cComposite defined as history of IV pulse steroids and daily corticosteroids
for ≥ 1 month
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contractures (OR 4.499, 95% CI 2.106–9.609), rituxi-
mab use (OR 3.955, 95% CI 1.551–10.089), and IVIG
use (OR 1.891, 95% CI 1.062–3.366), as shown in Fig. 1.
Outcomes of calcinosis
Of the 631 patients included in analysis, only 422 had at
least one follow-up visit. We reviewed the history of
calcinosis in these 422 patients through the first
follow-up visit. At baseline enrollment, 356 (84%) pa-
tients never had calcinosis and did not develop it
through the first follow-up visit. A total of 42 patients
had calcinosis present at the time of registry enrollment,
and in 11 (26%) of these patients, the calcinosis resolved
by the first follow-up visit, while in 31 (74%) patients,
Table 2 Clinical characteristics by history of calcinosis
Risk factor Descriptive analysis Univariable analysis
Calcinosis OR [95% CI] p-value
Yes No
Gender n (%) 0.0138
Male 33 (39.3) 144 (26.3) 1.811 [1.123–2.919] 0.0148
Female 51 (60.7) 403 (73.7)
Age (years) median (IQR)
At symptom onset 6 (4.2–9) 5.5 (3.6–9.3)
At diagnosis 8 (5.4–10.6) 6.3 (4.2–9.8) 0.0424
Time to diagnosis (months) 8.8 (2–23.6) 3.8 (1.9–8.9) 0.0011 1.029 [1.016–1.043] < 0.0001
Ethnicity n (%)
Hispanic 12 (14.3) 83 (15.2)
Race 0.0047
Caucasian 61 (72.6) 458 (83.7)
African-American 19 (22.6) 63 (11.5) 2.264 [1.270–4.038] 0.0056
Missing 4 (4.8) 26 (4.8)
JDM Category n (%)
Amyopathic 2 (2.4) 7 (1.3)
Probable 61 (72.6) 429 (78.4)
Definite 8 (9.5) 40 (7.3)
Missing 13 (15.5) 71 (13)
Clinical features n (%)
Lipodystrophy 11 (13.1) 13 (2.4) < 0.0001 5.993 [2.588–13.874] < 0.0001
Joint contractures 23 (27.4) 35 (6.4) < 0.0001 5.343 [2.964–9.635] < 0.0001
Cutaneous ulceration 12 (13.5) 23 (4.2) 0.001 3.748 [1.787–7.862] 0.0005
Gottron’s or Heliotrope 50 (59.5) 244 (44.6) 0.0176 1.754 [1.099–2.800] 0.0186
Dysphagia or dysphonia 26 (31) 107 (19.6) 0.0178
Small joint arthritis 25 (29.8) 115 (21.0) 0.041
Malar or facial erythema 31 (36.9) 182 (33.3)
V or Shawl sign 9 (10.7) 25 (4.6) 0.0377 2.410 [1.083–5.361] 0.0311
Periungal Telangiectasia 40 (47.6) 225 (41.1)
Cardiac involvement 4 (4.8) 10 (1.8)
Gastrointestinal ulceration 3 (3.6) 7 (1.3)
Interstitial lung disease 4 (4.8) 11 (2.0)
Any organ involvementa 9 (10.7) 25 (4.6) 0.0333 2.506 [1.127–5.573] 0.0243
Large joint arthritis 26 (31) 147 (26.9)
Muscle enzyme elevation 74 (88.1) 481 (87.9)
Severe muscle weakness 2 (2.4) 14 (2.6)
aComposite outcome: includes cardiac, GI or lung involvement
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the calcinosis persisted. There were 14 patients with a
prior history of but no calcinosis present at the time of
enrollment. Three of these patients would develop a re-
currence by the first follow-up visit.
Ten patients (2.5%) who never had calcinosis at the
time of baseline enrollment, developed calcinosis by the
first follow-up. The median age of JDM disease onset in
these patients was 7 (IQR 4.5–8.2) with a median age at
first follow-up (development of calcinosis) of 10.6 years
(IQR 9.8–12.4). It should be noted that age of JDM dis-
ease onset could be different from age of diagnosis, and
age of baseline enrollment. Eight patients were female.
Six patients were Caucasian, three patients African-
American and one patient mixed Caucasian and
Hispanic. At the time of baseline enrollment, one patient
had lipodystrophy, while one patient had joint contrac-
tures. For patients with available data, most (7/9, 78%)
had previously received IV pulse steroids, and 7/9 (78%)
were actively receiving daily long-term glucocorticoids
for at least 1 month’s duration. Four patients (50%) had
previously received IVIG and 4/8 (50%) were actively
receiving it. One patient had previously received ri-
tuximab (and also previously received IVIG), while
one patient was actively receiving rituximab but had
never received IVIG. None of the 10 patients had
ever received anti-TNF-alpha therapy, abatacept or
interleukin-1 inhibitors.
Discussion
Previous studies have highlighted differences between
patients with calcinosis and those without. Duration of
active JDM disease has been studied and described in
two ways: the duration of symptoms prior to initial diag-
nosis and treatment, and as chronically active disease
despite treatment. These two scenarios are not mutually
exclusive. When expressed as the time until diagnosis
Table 3 Treatment exposure by history of calcinosis
Risk factor Descriptive analysis Univariable analysis
Calcinosis OR [95% CI] p-value
Yes No
Biologic treatment (Ever) n (%)
Any biologic 48 (57.1) 194 (35.5) 0.0001 2.426 [1.522–3.867]
Rituximab 12 (14.3) 14 (2.6) < 0.0001 6.345 [2.825–14.254] < 0.001
IV Immune Globulin 45 (53.6) 180 (32.9) 0.0002 2.353 [1.479–3.743] 0.0003
Anti-TNF 12 (14.3) 23 (4.2) 0.0009 3.797 [1.812–7.960] 0.0004
Abatacept 2 (2.4) 1 (0.2) 0.048 13.317 [1.194–148.514] 0.0354
Anti-IL1 1 (1.2) 1 (0.2)
High steroid exposure 47 (56) 269 (54.3)
Fig. 1 Results of multivariate logistic regression analysis. Risk factors and event rates among patients with and without calcinosis are shown with
p-values. Forest plot displays odds ratios and associated 95% confidence intervals of multivariate logistic regression
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and treatment, increased symptom duration has been
shown to be a risk factor for the development of calcino-
sis in some studies [5, 11, 18, 29, 30] but not in others
[8, 19, 24], including a cohort with a high frequency of
calcinosis. When the duration of active disease is
expressed as chronically active disease despite treatment
(i.e. cumulative disease duration), an association with
calcinosis is also found in the studies that examined this
feature [5, 6]. The combination of these assessments has
led to the understanding that prolonged and/or severe
disease activity is a risk factor for calcinosis. This under-
standing has subsequently been tested, with some evi-
dence that early induction of remission can prevent
calcinosis [13, 14]. Myositis antibodies are now widely
used to guide prognosis and predict certain complica-
tions. In UK cohorts, calcinosis was associated with
positive anti-MJ antibodies [20, 21], but this was not
replicated in in a North American cohort, in which cal-
cinosis occurred with equal frequency in patients with
anti-p155/140, anti-MJ and negative serology [31].
African race, despite a low frequency of patients in all
JDM cohorts, has been shown to be a risk factor for calci-
nosis [15–17]. Previously, the only non-demographic clin-
ical features that were associated with calcinosis were
cardiac disease [19] and joint contractures [18].
To our knowledge, our study includes the largest
number of JDM patients with calcinosis collected and
analyzed as a single cohort. Compared to other inter-
national series, our demographic characteristics of sex,
age at onset, and JDM classification types are similar
[5–8, 16, 24, 29]. We found no association that the
age of JDM onset is associated with calcinosis. Male
sex was associated with calcinosis on univariate ana-
lysis but did not hold significance on multivariable
analysis. Our study demonstrated, as others have, that
a delay in diagnosis and treatment is associated with
the development of calcinosis; however, the effect in
our study was small (OR 1.029, 95% CI 1.013–1.045).
In addition, we showed that receiving IVIG or rituxi-
mab are more strongly associated with ever having
calcinosis, and with higher odds ratios (OR 1.891, OR
3.955 respectively) than those with treatment delays.
This effect was not seen with our variable of high
steroid exposure. Given that IVIG and rituximab are
typically reserved for those who fail standard treat-
ment, we suspect those patients had more severe
and/or prolonged active disease despite treatment.
Clearly, untreated disease represents a risk for devel-
oping calcinosis, as was demonstrated in early studies
with less effective treatments [2]. A delay in treat-
ment imparts this same risk, and based on the inter-
mittent association of this factor with calcinosis in
various studies, this suggests that the effect may pos-
sibly be mitigated with more effective treatment, in
addition to more timely treatment. Perhaps this im-
plies that at even greater risk are the types of disease
courses which are chronically active and difficult to
control. Many studies, including those focusing on
myositis antibodies are attempting to identify the
pathophysiological mechanisms underlying these dif-
ferences and therefore predict which patients might
be at risk of calcinosis. If reliable, such predictions
would encourage the development of screening tech-
niques and potentially inform treatment approaches.
In our study, we found that joint contractures (OR
4.499, 95% CI 2.106–9.609) and lipodystrophy (OR
3.038, 95% CI 1.014–9.106) were both independently
associated with developing calcinosis, the latter of
which to our knowledge has not been previously re-
ported. Cutaneous ulcerations and any organ involve-
ment (i.e. cardiac, pulmonary or gastrointestinal) were
also associated with calcinosis on univariate analyses
but did not hold significance in multivariate analysis.
These associations may not have been identified in
prior studies due to the small numbers of patients
with calcinosis as a whole in those studies. Addition-
ally, as collected in the legacy registry, the presence
or absence of disease features were assessed simply as
current, past or never without reference to chron-
ology. Calcinosis, particularly across a joint may lead
to joint contractures [9], which may partially explain
this association. Previously, calcinosis was also identi-
fied as a predictor for lipodystrophy with affected
areas often overlying areas of calcinosis or panniculi-
tis [32]. By reviewing the limited follow-up data in
the registry, we also describe that calcinosis occurs
infrequently in this cohort over a short time period
(2.5% of patients with one follow-up visit), but calci-
nosis tends to persist or recur once it has developed.
It is also noted that in the 10 patients who developed
calcinosis, most had received IVIG and/or rituximab
suggesting they had either severe or refractory dis-
ease, but none of these patients had received anti-
TNF-alpha therapy, since monoclonal antibody forms
have been shown to be effective against JDM disease
activity and calcinosis [33].
The limitations of our study include the retrospective
methodology and that patients enrolled in this registry
were a convenience sample with varying disease dura-
tions at the time of enrollment. Prior histories of treat-
ment and/or complications are subject to recall bias by
patients/parents and sufficient documentation at the
many respective enrolling centers. Information on calci-
nosis itself was limited only to its presence or absence
without further assessment of phenotype or complica-
tions such as infection. There was also no information
on whether treatments received by patients were specif-
ically intended for calcinosis or for other JDM disease
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activity. Additionally, information on testing of myositis-
specific and myositis-associated antibodies was not col-
lected. Further, there is inconsistent and relatively few
follow-up dates, as the funding for this registry was lim-
ited to a short duration of data capture. Given these
limitations, however, the CARRA legacy registry has pro-
vided important information about pediatric rheumatic
diseases and JDM. Many of these limitations have been
addressed in the newly created CARRA registry which
began enrolling patients in 2015 with plans for several
years of prospective follow-up. Apart from the full ration-
ale and methodology already published [34], there are spe-
cific improvements in the data capture for JDM and
calcinosis that address many of these limitations.
Conclusion
The pathogenesis and treatment approach for calcinosis
remains a frontier of research in Juvenile Dermatomyo-
sitis. Identifying patients at risk for the complication is a
critical step to improving treatment outcomes by focus-
ing research efforts. From studying a large registry of pa-
tients, we confirm prior reports that a delayed time to
diagnosis and treatment, joint contractures and organ
disease are associated with calcinosis, and we also found
that lipodystrophy is similarly associated. More aggres-
sive therapy, namely IVIG and rituximab, in our study
cohort is also associated with calcinosis which may
reflect chronically active or refractory disease.
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